Hims & Hers Expands into Menopause and Perimenopause Treatments, Targeting Growing Demand in Womenâs Health
A Major Move Into Womenâs Hormone Health
Hims & Hers Health has unveiled its latest expansion into menopause and perimenopause treatments, marking a significant step for the telehealth company as it extends its reach into one of the most under-addressed areas of womenâs healthcare. The companyâs new offerings focus on personalized care for hormonal changes, including hormone-replacement therapies (HRT), symptom management, and ongoing virtual consultations tailored to each patientâs needs.
According to Hims & Hers, this latest initiative reflects both a mission-driven and strategic decision. Around 1.3 million women enter menopause each year in the United States, yet a large portion receive inadequate or inconsistent care, especially when dealing with fluctuating hormones, hot flashes, sleep issues, and emotional changes that can accompany this stage of life.
Dr. Jessica Shepherd, the chief medical officer of Hers, noted that the service is not only a clinical expansion but also an opportunity to bridge a long-standing gap in care access. âThereâs an enormous underserved population of women experiencing menopause and perimenopause who deserve compassionate, evidence-based care,â she said in a company statement.
Building on a Digital Health Powerhouse
Founded in 2017, Hims & Hers Health began as a direct-to-consumer telehealth platform primarily serving millennial and Gen Z patients seeking discreet, affordable care for conditions like hair loss, anxiety, sexual health, and skincare. Over the years, it has steadily broadened its offerings, adding personalized treatment plans for both men and women through a hybrid model combining teleconsultations, prescriptions, and nationwide pharmacy distribution.
The companyâs move into menopause care signals a new chapterâone that positions Hers as more than a wellness brand. It aligns the platform with a growing push in the healthcare industry to recognize the full continuum of womenâs hormonal health, from early reproductive years through post-menopause.
Why Menopause is a Healthcare Gap
Despite affecting virtually half of the population, menopause has long remained a neglected area of modern medicine. Many women in midlife report feeling dismissed or inadequately treated by healthcare providers. In the U.S., just a small fraction of physicians receive formal training in menopause management. These gaps have led to an expanding patient population turning to telehealth for information and treatment options.
Symptoms vary widely, from hot flashes and night sweats to mood fluctuations, brain fog, and loss of sleep. According to the North American Menopause Society, nearly 80 percent of women experience these symptoms, but fewer than 20 percent receive any form of HRT or targeted medical support. This imbalance has created an opportunity for digital platforms like Hers to tailor care beyond traditional clinic walls.
Inside the New Hers Menopause Platform
The newly launched Hers program integrates telemedicine, clinical diagnostics, and ongoing treatment management. Patients begin with an online consultation led by licensed healthcare professionals who specialize in hormonal health. The platform then provides access to prescription therapiesâranging from estrogen and progesterone modules to non-hormonal alternatives designed to alleviate specific symptoms.
Care plans are designed to evolve as the patient progresses through different phases of menopause. The subscription model offers continuous monitoring, automatic prescription refills, and optional video consultations. Hims & Hers emphasizes that treatment decisions are built on evidence-based medical guidelines rather than cosmetic or lifestyle factors.
Additionally, Hers has introduced educational resources to help patients understand the biological and psychological aspects of menopause. The companyâs medical team plans to host webinars and interactive Q&A sessions aimed at normalizing discussions around womenâs midlife health.
Competitive Landscape and Market Context
The telehealth industry is experiencing consolidation and specialization, and menopause care represents one of its fastest-growing niches. New entrants such as Midi Health, Evernow, and Alloy have already signaled the sectorâs potential, collectively raising millions in venture funding and amassing large patient waitlists. Hims & Hers, however, holds a unique advantage: scale.
With an established customer base of both male and female patients, the company operates a vertically integrated model that includes licensing, teleconsultations, and nationwide pharmacy fulfillment. By leveraging this existing infrastructure, Hims & Hers can potentially reach millions of current users without starting from scratch.
Industry analysts indicate that the menopausal health market, valued at approximately $15 billion globally, could surpass $25 billion by 2030 as awareness grows and stigma declines. Digital solutions allowing women to access care from home are expected to play a key role in this expansion.
Economic Impact and Growth Projections
Hims & Hers views the menopause and perimenopause expansion as a cornerstone of its growth strategy for 2026. The company projects that this new specialty alone could help propel annual revenue for the Hers division beyond $1 billion next year.
This forecast reflects both increased consumer awareness and the companyâs move into higher-value care categories such as hormone therapy, a segment with significantly stronger margins compared to over-the-counter wellness products.
Telehealth usage rates have stabilized since the post-pandemic surge, but chronic and long-term care segmentsâsuch as menopause, mental health, and weight managementâcontinue to drive sustainable demand. By diversifying within these categories, Hims & Hers aims to insulate itself from broader telehealth slowdowns while growing recurring revenue streams.
Historical Perspective on Hormone Replacement Therapy
Hormone replacement therapy has a complicated history in the U.S. In the late 20th century, HRT gained widespread popularity before a major 2002 study by the Womenâs Health Initiative linked certain formulations to increased health risks. Those findings prompted an abrupt decline in prescriptions and a hesitancy among many healthcare providers to recommend treatment. Subsequent research has since refined understanding of the associated risks, emphasizing the importance of personalized regimens.
Today, medical consensus supports that for most healthy women who begin HRT near the onset of menopause, the benefitsâincluding protection against osteoporosis and relief from vasomotor symptomsâoutweigh the potential risks when monitored appropriately. By offering remote, tailored medical oversight, Hims & Hers seeks to integrate this evolving science into scalable care delivery.
Broader Implications for Telemedicine
The companyâs entrance into menopause care underscores a broader industry trend: the shifting of long-term and specialized healthcare toward digital ecosystems. While telehealth initially gained traction for convenience-based services, its role now extends into chronic care management, behavioral health, fertility support, and now hormonal therapy.
Experts suggest that menopause care could become a major proving ground for patient engagement models built around trust, accessibility, and education. The ability to combine medical expertise with a consumer-friendly digital experience may become central to how womenâs health evolves in the coming decade.
Hims & Hers also plans to utilize anonymized patient data to better understand trends in symptom onset, treatment efficacy, and demography. These insights could shape not just individualized care but also inform future clinical research partnerships.
Comparing Regional Demand Across Markets
In the United States, menopause care remains fragmented, with considerable variability by region. Urban centers like New York, Los Angeles, and Chicago have growing networks of specialized clinics, while rural regions often lack dedicated resources. This uneven distribution has amplified interest in telemedicine as an equalizer.
In Europe, the United Kingdom and several Nordic countries have seen a similar digital movement, with menopause clinics offering remote consultations covered under national health schemes. Meanwhile, Asia-Pacific markets, particularly in Australia and Japan, are witnessing rising corporate investment in midlife wellness. Hims & Hers, though primarily U.S.-focused, has hinted at potential international expansion once regulatory frameworks allow.
Public Reaction and Future Outlook
Public response to the announcement has been decidedly positive. Online discussions across health forums and social platforms feature women welcoming a major telehealth company addressing this life stage with seriousness and expertise. Early users of the Hers program cite convenience, affordability, and relief at finding physicians trained specifically in menopause care as standout benefits.
Analysts view the expansion not just as a strategic business maneuver, but as a cultural signal: menopause is finally entering mainstream healthcare conversations. Hims & Hersâ decisive entry may accelerate further innovation, pushing both startups and traditional healthcare systems to address aging and hormonal transitions with the same sophistication applied to reproductive and fertility care.
As the company gears up for what it describes as a ânew era of inclusive, lifecycle-focused telehealth,â its success will depend on the ability to maintain medical rigor while scaling access. The challengesâregulatory oversight, continuity of care, and integration with in-person systemsâremain substantial, but the potential upside is equally clear.
With a strong platform, a growing patient base, and a focus on holistic health, Hims & Hers is positioning itself to redefine how menopause care is experienced in the digital ageâmaking what was once a stigmatized conversation part of everyday healthcare.